1 asset in Trigeminal Nerve Disorder

Therapeutic assets addressing Trigeminal Nerve Disorder, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Immunoglobulin G, Anti-(Human Calcitonin Gene-Related Peptide Receptor) (Human Monoclonal Heavy Chain), Disulfide With Human Monoclonal Light Chain, Dimer Trigeminal Nerve Disorder	University of Maryland, Baltimore	P2	CCC (53)